Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

NCT02358473 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: mogamulizumab
DRUG: Docetaxel

Sponsor

Kyowa Kirin, Inc.